Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-2524 Combined With Bevacizumab in Advanced Hepatocellular Carcinoma
NCT07478302Phase 1Recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Apr 2026
- Primary completion
- Oct 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SHR-2524 in hepatocellular carcinoma (HCC), sponsored by Suzhou Suncadia Biopharmaceutical. Primary endpoints: Trough serum concentrations, Area under curve from Day 0 to Day 21 and 1 more. Started Apr 2026; status: recruiting.
02
Drugs
SHR-2524
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07478302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07478302.